Taivex announced that its Phase I clinical trial drugs, T-1101 and T-1201, have been invited to present their project progress at the Korean Society of
Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Taivex will attend the Bio Asia-Taiwan 2024, BIO
The groundbreaking discovery and development of T-1201, a novel targeting small molecule-drug conjugate (SN38), and T-1301, an innovative multi-targeted tyrosine kinase inhibitor (TKI), have been
Taivex has announced that all three Phase I clinical projects, T-1101, T-1201, and T-1301, have been selected to present their project progress at the American
Taivex Therapeutics attended the 2024 BIO-Europe SPRING conference in Barcelona, Spain (https://informaconnect.com/bioeurope-spring/) from March 18th to 20th. During the conference, Taivex engaged in discussions with
T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient
The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase
National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June
